These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 33651883)

  • 1. Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
    Vitale C; Salvetti C; Griggio V; Porrazzo M; Schiattone L; Zamprogna G; Visentin A; Vassallo F; Cassin R; Rigolin GM; Murru R; Laurenti L; Rivela P; Marchetti M; Pennese E; Gentile M; Boccellato E; Perutelli F; Montalbano MC; De Paoli L; Reda G; Orsucci L; Trentin L; Cuneo A; Tedeschi A; Scarfò L; Gaidano G; Mauro FR; Foà R; Boccadoro M; Coscia M
    Blood; 2021 Jun; 137(25):3507-3517. PubMed ID: 33651883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells.
    Nabergoj S; Markovič T; Avsec D; Gobec M; Podgornik H; Jakopin Ž; Mlinarič-Raščan I
    Biochem Pharmacol; 2021 Jan; 183():114352. PubMed ID: 33278351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
    Jain N; Keating M; Thompson P; Ferrajoli A; Burger J; Borthakur G; Takahashi K; Estrov Z; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Sasaki K; Kanagal-Shamanna R; Patel K; Jorgensen J; Garg N; Wang X; Sondermann K; Cruz N; Wei C; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda W
    N Engl J Med; 2019 May; 380(22):2095-2103. PubMed ID: 31141631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
    Coutre S; Choi M; Furman RR; Eradat H; Heffner L; Jones JA; Chyla B; Zhou L; Agarwal S; Waskiewicz T; Verdugo M; Humerickhouse RA; Potluri J; Wierda WG; Davids MS
    Blood; 2018 Apr; 131(15):1704-1711. PubMed ID: 29305552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
    Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
    JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
    Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
    Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
    Huber H; Edenhofer S; von Tresckow J; Robrecht S; Zhang C; Tausch E; Schneider C; Bloehdorn J; Fürstenau M; Dreger P; Ritgen M; Illmer T; Illert AL; Dürig J; Böttcher S; Niemann CU; Kneba M; Fink AM; Fischer K; Döhner H; Hallek M; Eichhorst B; Stilgenbauer S
    Blood; 2022 Mar; 139(9):1318-1329. PubMed ID: 35108374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.
    Stefania Infante M; Fernández-Cruz A; Núñez L; Carpio C; Jiménez-Ubieto A; López-Jiménez J; Vásquez L; Del Campo R; Romero S; Alonso C; Morillo D; Prat M; Luis Plana J; Villafuerte P; Bastidas G; Bocanegra A; Serna Á; De Nicolás R; Marquet J; Mas-Ochoa C; Cordoba R; García-Suárez J; Comai A; Martín X; Bastos-Oreiro M; Seri C; Navarro-Matilla B; López-Guillermo A; Martínez-López J; Ángel Hernández-Rivas J; Ruiz-Camps I; Grande C;
    Cancer Med; 2021 Nov; 10(21):7629-7640. PubMed ID: 34558211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.
    O'Brien SM; Lamanna N; Kipps TJ; Flinn I; Zelenetz AD; Burger JA; Keating M; Mitra S; Holes L; Yu AS; Johnson DM; Miller LL; Kim Y; Dansey RD; Dubowy RL; Coutre SE
    Blood; 2015 Dec; 126(25):2686-94. PubMed ID: 26472751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
    Innocenti I; Morelli F; Autore F; Piciocchi A; Frustaci A; Mauro FR; Schiattone L; Trentin L; Del Poeta G; Reda G; Rigolin GM; Ibatici A; Ciolli S; Coscia M; Sportoletti P; Murru R; Levato L; Gentile M; D'Arena G; Efremov DG; Tedeschi A; Scarfò L; Cuneo A; Foà R; Laurenti L
    Br J Haematol; 2019 Oct; 187(1):e8-e11. PubMed ID: 31364153
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Haselager MV; Kielbassa K; Ter Burg J; Bax DJC; Fernandes SM; Borst J; Tam C; Forconi F; Chiodin G; Brown JR; Dubois J; Kater AP; Eldering E
    Blood; 2020 Dec; 136(25):2918-2926. PubMed ID: 32603412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
    Schwaner I; Kuhn T; Losem C; Wolff T; Otremba B; Zaiss M; Hülsenbeck J; Famulla K; Nösslinger T; Rossi D
    Ann Hematol; 2024 Jun; 103(6):2013-2020. PubMed ID: 38421404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia.
    Edelmann J; Gribben JG
    J Oncol Pract; 2017 Jun; 13(6):371-377. PubMed ID: 28605616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
    Molica S; Giannarelli D; Montserrat E
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):216-223. PubMed ID: 33199185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
    Cramer P; von Tresckow J; Bahlo J; Engelke A; Langerbeins P; Fink AM; Fischer K; Wendtner CM; Kreuzer KA; Stilgenbauer S; Böttcher S; Eichhorst B; Hallek M
    Future Oncol; 2018 Mar; 14(6):499-513. PubMed ID: 29465308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL.
    Skånland SS; Cremaschi A; Bendiksen H; Hermansen JU; Thimiri Govinda Raj DB; Munthe LA; Tjønnfjord GE; Taskén K
    Leukemia; 2020 Feb; 34(2):478-487. PubMed ID: 31471562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
    Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
    Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
    Brown JR; Hallek MJ; Pagel JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.